Assignee
CUGENE INC
US·4 granted patents·8 pending applications·4 citations·filing 2019–2025
Top patents by PatentIndex Score
12 records- 0192US12152060B2Interleukin-2 variants and methods of uses thereofCUGENE INC·Filed 2023·Granted Nov 26, 2024·1 cites·6 claims
- 0288US11634467B2Cytokine-based bioactivatable drugs and methods of uses thereofCUGENE INC·Filed 2019·Granted Apr 25, 2023·3 cites·9 claims
- 0380US12319723B2Cytokine-based bioactivatable drugs and methods of uses thereofCUGENE INC·Filed 2023·Granted Jun 3, 2025·0 cites·9 claims
- 0477US2024254185A1Interleukin-2 variants and methods of uses thereofCUGENE INC·Filed 2024·Application pending·0 cites
- 0569US12319722B2Interleukin-15 (IL-15) fusion proteins and uses thereofCUGENE INC·Filed 2019·Granted Jun 3, 2025·0 cites·12 claims
- 0666US2026078159A1NOVEL PD1-TARGETED IL-15 IMMUNOCYTOKINE and VITOKINE FUSIONSCUGENE INC·Filed 2023·Application pending·0 cites
- 0766US2025388641A1Novel interleukin-15 (il-15) fusion proteins and uses thereofCUGENE INC·Filed 2025·Application pending·0 cites
- 0858US2021269497A1Interleukin-2 variants and methods of uses thereofCUGENE INC·Filed 2019·Application pending·0 cites
- 0952US2022170028A1Novel interleukin-2 variants and bifunctional fusion molecules thereofCUGENE INC·Filed 2020·Application pending·0 cites
- 1052US2023048046A1Novel interleukin-15 (il-15) fusion proteins and uses thereofCUGENE INC·Filed 2020·Application pending·0 cites
- 1152US2023093155A1Cytokine-based bioactivatable drugs and methods of uses thereofCUGENE INC·Filed 2020·Application pending·0 cites
- 1251US2022235109A1Novel interleukin-2 variants for the treatment of cancerCUGENE INC·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →